The diagnostic yield of the survivin gene in patients with lung cancer

It has been discovered that many solid tumors express the survivin gene, particularly in tissue samples. On the other hand, limited data exist on the significance of the survivin gene in bronchial aspirates from lung cancer patients. The current study was designed to evaluate the levels of the survivin gene in lung cancer patients and correlate them with other clinical features. The study population consisted of 58 patients with lung cancer. A total of 25 patients with non-malignant lung diseases were used as a comparable group. We used real-time quantitative reverse transcription polymerase chain reaction to assess survivin gene level in bronchial aspirate during bronchoscopy from individuals with lung cancer, as well as those with benign lung diseases. Cases with lung cancer had bronchial aspirates with a substantially greater survivin gene level (3.7±1.8) compared to individuals with benign lung illnesses (1.1±0.9) (p=0.0001). The lung cancer diagnosis had a sensitivity of 74.14% and a specificity of 96% when 2.4 of the survivin gene was used as the cutoff value. The levels of the survivin gene in lung cancer patients were significantly positively correlated with both age and performance status, with p values of 0.012 and 0.0001, respectively. Nonetheless, there was a negative connection between the survivin gene level and the length of symptoms as well as the survival time in months, with p-values of 0.027 and 0.001, respectively. As a molecular marker, survivin gene identification in bronchial aspirate has both diagnostic and prognostic significance for lung cancer.